Paclical is indicated for ovarian cancer and lung cancer.
Oasmia has developed a water soluble formulation of Paclitaxel with the retinoid based platform XR-17.
Oasmia claims Paclitaxel does not require premedication and shows a different side effect profile compared to Taxol.
As per the terms of the agreement, Medison is responsible to pay a sum of EUR400,000 as an upfront payment to Oasmia including milestone payments and additional royalties on all sales in the region.
Oasmia has previously closed a license and distribution agreement of Paclical for the Nordics with Orion in Finland.
Medison president and CEO Meir Jakobsohn said they are proud to expand their portfolio with Paclical, which will be part of their vast Oncology line and it’s a great annunciation for the patients and health community in Israel and Turkey.
Headquartered in Petach Tikva, Israel, Medison Pharma is a marketing group that provides the integrated services for international companies looking to enter or expand their presence in the Israeli, Romanian and Slovakian healthcare markets.